Stem cells, cell therapies, and bioengineering in lung biology and diseases 2017

Amy L. Ryan, Molecular Biology Stem Cell Working Group Subcommittee, on behalf of the American Thoracic Society Assembly on Respiratory Cell, Laertis Ikonomou, Sadaf Atarod, Deniz A. Bölükbas, Jennifer Collins, Rob Freishtat, Finn Hawkins, Sarah E. Gilpin, Franziska E. Uhl, Juan Jose Uriarte, Daniel J. Weiss, Darcy E. Wagner*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)

Abstract

The University of Vermont Larner College of Medicine, in collaboration with the National Heart, Lung, and Blood Institute (NHLBI), the Alpha-1 Foundation, the American Thoracic Society, the Cystic Fibrosis Foundation, the European Respiratory Society, the International Society for Cell & Gene Therapy, and the Pulmonary Fibrosis Foundation, convened a workshop titled "Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases" from July 24 through 27, 2017, at the University of Vermont, Burlington, Vermont. The conference objectives were to review and discuss current understanding of the following topics: 1) stem and progenitor cell biology and the role that they play in endogenous repair or as cell therapies after lung injury, 2) the emerging role of extracellular vesicles as potential therapies, 3) ex vivo bioengineering of lung and airway tissue, and 4) progress in induced pluripotent stem cell protocols for deriving lung cell types and applications in disease modeling. All of these topics are research areas in which significant and exciting progress has been made over the past few years. In addition, issues surrounding the ethics and regulation of cell therapies worldwide were discussed, with a special emphasis on combating the growing problem of unproven cell interventions being administered to patients with lung diseases. Finally, future research directions were discussed, and opportunities for both basic and translational research were identified.

Original languageEnglish
Pages (from-to)429-439
Number of pages11
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume61
Issue number4
DOIs
Publication statusPublished - 1 Oct 2019

Bibliographical note

Funding Information:
Author Disclosures: D.E.W. received grants from Acell, Alpha-1 Foundation, Athersys, Biostage, Cystic Fibrosis Foundation, Pulmonary Fibrosis Foundation, and United Therapeutics; served as a speaker for Boehringer Ingelheim; has ownership or investment interest in Pfizer; and holds U.S. Provisional Patent Application No. 61/810,966 for System and Method for Decellularization and Recellularization of Whole Organs. D.J.W. received grants from Acell, Alpha-1 Foundation, Athersys, Biostage, Cystic Fibrosis Foundation, and United Therapeutics. A.L.R., L.I., S.A., D.A.B., J.C., R.F., F.H., S.E.G., F.E.U., and J.J.U. reported no relevant commercial relationships.

Publisher Copyright:
Copyright © 2019 by the American Thoracic Society

Fingerprint

Dive into the research topics of 'Stem cells, cell therapies, and bioengineering in lung biology and diseases 2017'. Together they form a unique fingerprint.

Cite this